Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.67 |
| ▸ | EBP | Q15125 | 4/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.50 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16910242 | 0.93 | SIGMAR1 (0.69) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| Citric Acid SCHEMBL17164694 | 0.90 | KDM4E (0.59) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL2896442 | 0.88 | CYP2D6 (0.54) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL3294808 | 0.88 | CYP2D6 (0.54) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL7753432 | 0.87 | SIGMAR1 (0.79) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL8707174 | 0.86 | EBP (0.56) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL4310502 | 0.86 | EBP (0.81) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL4314565 | 0.84 | EBP (0.53) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL10356744 | 0.83 | CYP2D6 (0.58) | SIGMAR1EBPCYP2D6HTTCYP1A2 | |
| SCHEMBL10368035 | 0.82 | HTT (0.56) | SIGMAR1HTTCYP1A2LTA4HCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 505 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118477176-A | Estrogen analogue, estrogen receptor activator and application thereof | 广州国家实验室 | 2024-08-13 | — | — | CN | claimed |
| US-11850306-B2 | Method for drying hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose | UPM-KYMMENE CORPORATION (FI) | 2023-12-26 | — | — | US | claimed |
| US-20200360411-A1 | REPURPOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER STEM CELLS | LUNELLA BIOTECH, INC. (CA) | 2020-11-19 | — | — | US | claimed |
| EP-3717015-A1 | REPURPOSCINS: TARGETED INHIBITORS OF MITOCHONDRIAL BIOGENESIS FOR ERADICATING CANCER STEM CELLS | Lunella Biotech, Inc. (CA) | 2020-10-07 | — | — | EP | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | WYETH LLC (US) | 2012-08-30 | — | — | US | claimed |
| US-8147561-B2 | Methods and devices to curb appetite and/or reduce food intake | ENDOSPHERE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20110295337-A1 | Systems and Methods For Regulating Metabolic Hormone Producing Tissue | ETHICON ENDO-SURGERY, INC. | 2011-12-01 | — | — | US | claimed |
| EP-0723439-B1 | COMBINATION OF PROGESTERONE ANTAGONISTS AND ANTI-OESTROGENS WITH PARTIAL AGONISTIC ACTION FOR USE IN HORMONE-REPLACEMENT THERAPY FOR PERI- AND POST-MENOPAUSAL WOMEN | SCHERING AG (DE) | 2000-09-13 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5733902-A | Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-03-31 | — | — | US | claimed |
| US-5719136-A | Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | claimed |
| US-5650425-A | ANTICARCINOGENIC, ANTAGONIST, ANTITUMOR AGENTS AND ANTIINFLAMMATORY AGENTS | PHARMOS CORPORATION (US) | 1997-07-22 | — | — | US | claimed |
| EP-0754036-A1 | PERMANENTLY IONIC DERIVATIVES OF STEROID HORMONES AND THEIR ANTAGONISTS | PHARMOS CORPORATION (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026720-A1 | PERMANENTLY IONIC DERIVATIVES OF STEROID HORMONES AND THEIR ANTAGONISTS | PHARMOS CORPORATION (US) | 1995-10-12 | — | — | WO | claimed |
| US-4894373-A | CLOMIPHEN, ISOMERS AND SALTS | BCM TECHNOLOGIES, INC. (US) | 1990-01-16 | — | — | US | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4310523-A | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220558-A1 | Methods of Treating Hormone-Related Conditions Using Thio-Oxindole Derivatives | OXTR, GNRHR, SHBG | SIGMAR1 217/4885EBP 1971/4885CYP2D6 361/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | SIGMAR1 1981/4885EBP 3677/4885CYP2D6 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.